Alembic Pharmaceuticals Limited — Updates, 15-05-2025: Press Release

Alembic Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. The company secured USFDA final approval for Rivaroxaban Tablets USP in four strengths, unlocking access to a US$8.5 billion market. The 2.5 mg strength, valued at US$445 million, is slated for launch in Q1FY26. This approval boosts Alembic’s US portfolio to 222 ANDA approvals, enhancing growth prospects in the competitive US generics space.